A5004165966- Pituitary Gland Disorders and Treatments
- Adrenal and Paraganglionic Tumors
- Cancer, Hypoxia, and Metabolism
- Adrenal Hormones and Disorders
- Hormonal Regulation and Hypertension
- Glioma Diagnosis and Treatment
- Thyroid Disorders and Treatments
- Vitamin D Research Studies
- Diet and metabolism studies
- Estrogen and related hormone effects
- Cholinesterase and Neurodegenerative Diseases
- Alzheimer's disease research and treatments
- Growth Hormone and Insulin-like Growth Factors
- Parathyroid Disorders and Treatments
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Medical and Biological Sciences
- Hormonal and reproductive studies
- Diabetes and associated disorders
- Signaling Pathways in Disease
- Iron Metabolism and Disorders
- Regulation of Appetite and Obesity
- Cancer, Lipids, and Metabolism
- Adipokines, Inflammation, and Metabolic Diseases
- RNA regulation and disease
- Lipoproteins and Cardiovascular Health
Centre Hospitalier de l’Université de Montréal
2020-2024
Université de Montréal
2023
Assistance Publique – Hôpitaux de Paris
2022-2023
Université Laval
2019
To determine whether vitamin D3 supplementation improves insulin sensitivity, using the hyperinsulinemic-euglycemic clamp.This single-centre, double-blind, placebo-controlled trial randomised 96 participants at high risk of diabetes or with newly diagnosed type 2 to 5000 IU daily placebo for 6 months.We assessed baseline and months: (1) primary aim: peripheral sensitivity (M-value a 2-h clamp); (2) secondary aims: other (HOMA2%S, Matsuda) secretion (insulinogenic index, C-peptide area under...
Abstract Introduction Osilodrostat is the newest approved steroidogenic inhibitor drug for treatment of hypercortisolism. In this article, we describe 3 patients who experienced a previously undescribed adverse event: prolonged adrenocortical blockade following cessation. Methods Patient records showing history successful hypercortisolism control with followed by at least 4 weeks interruption were reviewed. characteristics and hormonal dosage analyzed. Results Persistence was found in lasted...
Osilodrostat is a new 11β-hydroxylase inhibitor with mode of action analogous to Metyrapone. The objective this study was compare steroidogenic profiles in patients treated either or Metyrapone for adrenocorticotrophic hormone (ACTH)-dependent Cushing's syndrome (CS).Patients followed up at Cochin hospital Endocrinology department between March 2019 and December 2021 an ACTH-dependent CS, controlled by Metyrapone, were included. A serum profile five steroids (cortisol, 11-deoxycortisol,...
Mitotane is a steroidogenesis inhibitor and adrenolytic drug used for treatment of adrenocortical cancer (ACC). therapy causes adrenal insufficiency requiring glucocorticoid replacement in all patients. However, it unclear whether chronic with mitotane induces complete destruction zona fasciculata hypothalamic-pituitary-adrenal (HPA) axis can recover after cessation. Our objective was to assess the HPA recovery cohort patients cessation adjuvant ACC. We retrospectively reviewed patient files...
The role of cytoreduction adrenocortical carcinoma (ACC) remains poorly understood.To analyze the impact cytoreductive surgery primary tumor in patients with metastatic ACC.We performed a multicentric, retrospective paired cohort study comparing overall survival (OS) ACC who were treated either (CR group) or without (no-CR tumor. Data retrieved from 9 referral centers American-Australian-Asian Adrenal Alliance collaborative research group.Patients aged ≥18 years at initial presentation...
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
Abstract Context: Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 0.7-2 per million. Based on the ENSAT staging classification, stage most important prognostic factor; presence lymph nodes involvement and metastases indicator poor prognosis. Absence any local or distant invasion represents early disease classified based size <5 cm (stage I) >5 II). Advanced confirmed if there tumoral invasion, either locally in surrounding tissues/nodes III) other...
Abstract Context. Mitotane is a steroidogenesis inhibitor and an adrenocorticolytic drug used to treat adrenocortical cancer (ACC). Central hypothyroidism recognized in mitotane-treated patients recent data suggested that mitotane could have inhibitory effect on TSH-secreting cells the pituitary gland. Moreover, may lead induction of thyroid hormone metabolism. Clinical related such as prevalence time occurrence was described limited number patients. Objective. To better characterize...